Boston Common Asset Management, LLC Gilead Sciences, Inc. Transaction History

Boston Common Asset Management, LLC

  • $3.84 Billion
  • Q3 2024

A detailed history of Boston Common Asset Management, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Boston Common Asset Management, LLC holds 169,283 shares of GILD stock, worth $15.5 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
169,283
Previous 183,450 7.72%
Holding current value
$15.5 Million
Previous $12.6 Million 12.76%
% of portfolio
0.37%
Previous 0.32%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024
SELL
$66.59 - $83.99 $943,380 - $1.19 Million
-14,167 Reduced 7.72%
169,283 $14.2 Million
Q2 2024

Jul 08, 2024
SELL
$63.15 - $72.88 $3.14 Million - $3.63 Million
-49,759 Reduced 21.34%
183,450 $12.6 Million
Q1 2024

Apr 11, 2024
SELL
$71.58 - $87.29 $2.25 Million - $2.75 Million
-31,494 Reduced 11.9%
233,209 $17.1 Million
Q4 2023

Jan 09, 2024
SELL
$73.27 - $83.09 $4.52 Million - $5.12 Million
-61,644 Reduced 18.89%
264,703 $21.4 Million
Q3 2023

Oct 11, 2023
SELL
$73.94 - $80.67 $5.62 Million - $6.13 Million
-75,978 Reduced 18.88%
326,347 $24.5 Million
Q2 2023

Jul 24, 2023
SELL
$76.01 - $86.7 $3.51 Million - $4.01 Million
-46,217 Reduced 10.3%
402,325 $31 Million
Q1 2023

May 17, 2023
SELL
$77.31 - $88.08 $4.12 Million - $4.69 Million
-53,254 Reduced 10.61%
448,542 $37.2 Million
Q4 2022

Jan 26, 2023
SELL
$62.32 - $89.47 $1.45 Million - $2.09 Million
-23,333 Reduced 4.44%
501,796 $43.1 Million
Q3 2022

Oct 20, 2022
BUY
$59.54 - $68.01 $12.6 Million - $14.4 Million
211,666 Added 67.53%
525,129 $32.4 Million
Q2 2022

Aug 10, 2022
BUY
$57.72 - $65.01 $6.43 Million - $7.24 Million
111,432 Added 55.16%
313,463 $19.4 Million
Q1 2022

May 16, 2022
SELL
$57.92 - $72.58 $5.83 Million - $7.31 Million
-100,725 Reduced 33.27%
202,031 $12 Million
Q4 2021

Jan 31, 2022
BUY
$64.88 - $73.64 $67,410 - $76,511
1,039 Added 0.34%
302,756 $22 Million
Q3 2021

Nov 12, 2021
SELL
$67.69 - $73.03 $90,433 - $97,568
-1,336 Reduced 0.44%
301,717 $21.1 Million
Q2 2021

Aug 19, 2021
BUY
$63.47 - $69.35 $17.4 Million - $19 Million
274,067 Added 945.52%
303,053 $20.9 Million
Q1 2021

May 14, 2021
SELL
$60.0 - $68.46 $12 Million - $13.7 Million
-200,198 Reduced 87.35%
28,986 $1.87 Million
Q4 2020

Feb 05, 2021
BUY
$56.65 - $64.55 $3.43 Million - $3.91 Million
60,519 Added 35.88%
229,184 $13.4 Million
Q3 2020

Nov 10, 2020
SELL
$62.1 - $78.08 $94,578 - $118,915
-1,523 Reduced 0.89%
168,665 $10.7 Million
Q2 2020

Aug 10, 2020
BUY
$72.34 - $84.0 $493,648 - $573,216
6,824 Added 4.18%
170,188 $13.1 Million
Q1 2020

May 08, 2020
BUY
$62.63 - $80.22 $6.9 Million - $8.84 Million
110,214 Added 207.36%
163,364 $12.2 Million
Q4 2019

Jan 28, 2020
BUY
$61.62 - $67.78 $776,412 - $854,028
12,600 Added 31.07%
53,150 $3.45 Million
Q3 2019

Nov 07, 2019
BUY
$62.51 - $69.0 $83,138 - $91,770
1,330 Added 3.39%
40,550 $2.57 Million
Q2 2019

Jul 26, 2019
BUY
$61.87 - $69.38 $2.43 Million - $2.72 Million
39,220 New
39,220 $2.65 Million
Q3 2018

Nov 01, 2018
SELL
$71.28 - $78.92 $207,353 - $229,578
-2,909 Closed
0 $0
Q2 2018

Aug 06, 2018
SELL
$64.88 - $75.68 $4.62 Million - $5.39 Million
-71,254 Reduced 96.08%
2,909 $206,000
Q1 2018

Apr 26, 2018
BUY
$72.84 - $88.8 $241,100 - $293,928
3,310 Added 4.67%
74,163 $5.59 Million
Q4 2017

Feb 07, 2018
SELL
$71.15 - $83.52 $346,998 - $407,327
-4,877 Reduced 6.44%
70,853 $5.08 Million
Q3 2017

Nov 13, 2017
BUY
$72.11 - $85.47 $1.25 Million - $1.48 Million
17,351 Added 29.72%
75,730 $6.14 Million
Q2 2017

Aug 14, 2017
BUY
N/A
58,379
58,379 $4.13 Million

Others Institutions Holding GILD

# of Institutions
1,927
Shares Held
994M
Call Options Held
10.5M
Put Options Held
9.75M
View Full List

About GILEAD SCIENCES, INC.

GILD Quotes by TradingView
  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Boston Common Asset Management, LLC Portfolio

Follow Boston Common Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boston Common Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boston Common Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email